LPL Financial LLC Sells 4,335 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

LPL Financial LLC lessened its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 6.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 61,204 shares of the specialty pharmaceutical company’s stock after selling 4,335 shares during the quarter. LPL Financial LLC’s holdings in Collegium Pharmaceutical were worth $1,753,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of COLL. KBC Group NV lifted its stake in Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 982 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 316 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after purchasing an additional 642 shares during the last quarter. Aigen Investment Management LP bought a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at about $230,000. Finally, Summit Global Investments acquired a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth about $232,000.

Collegium Pharmaceutical Trading Down 0.4 %

NASDAQ:COLL opened at $27.02 on Thursday. The company has a market cap of $868.21 million, a PE ratio of 11.65 and a beta of 0.76. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $42.29. The firm has a 50-day moving average of $28.90 and a 200-day moving average of $31.41.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 977 shares of Collegium Pharmaceutical stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now directly owns 164,269 shares in the company, valued at approximately $4,928,070. The trade was a 0.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 2,255 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the sale, the executive vice president now directly owns 124,421 shares in the company, valued at $3,732,630. This trade represents a 1.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,693 shares of company stock worth $2,334,994 in the last ninety days. Company insiders own 3.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on COLL. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler dropped their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Finally, StockNews.com upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 11th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Collegium Pharmaceutical has an average rating of “Buy” and an average target price of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.